Can Sacubitril-Valsartan Cause Cholestasis?
Sacubitril-valsartan can cause cholestatic liver injury, though this is extremely rare, and clinicians should monitor liver function during treatment, particularly in the first few months of therapy.
Evidence for Hepatotoxicity
The FDA drug label for Entresto (sacubitril-valsartan) does not specifically list cholestasis as a known adverse effect 1. However, a published case report from 2023 documented the first case of severe liver injury caused by sacubitril-valsartan in a 90-year-old female patient who developed serious hepatic transaminase elevations after starting the medication 2. The liver injury resolved completely after drug withdrawal, establishing a clear temporal relationship and causality.
Clinical Context and Mechanism
While sacubitril-valsartan-induced cholestasis appears to be exceptionally rare, any drug can theoretically cause drug-induced cholestatic liver injury (DILI) through idiosyncratic or hypersensitive mechanisms 3. The EASL guidelines note that several hundred drugs have been reported to trigger cholestatic injury, with prevalence typically between 1 in 10,000 and 1 in 100,000 patients, though this is likely underreported 3.
Drug-induced cholestasis is defined by:
- Isolated alkaline phosphatase >2× ULN, OR
- ALT/AP ratio (both elevated above ULN) <2 3
Paradoxical Hepatoprotective Effects
Interestingly, the PARADIGM-HF trial demonstrated that sacubitril-valsartan actually improved conventional measures of liver function compared to enalapril, with significant reductions in total bilirubin (2.4%), AST (7.9%), ALT (7.7%), and alkaline phosphatase (5.4%) 4. This suggests that in most patients, the drug may have beneficial effects on hepatic congestion related to heart failure.
Clinical Recommendations
If cholestatic liver injury is suspected:
Obtain a careful drug history and establish temporal relationship between sacubitril-valsartan initiation and liver test abnormalities 3
Exclude other causes of cholestasis through appropriate workup (viral hepatitis, autoimmune disease, biliary obstruction via ultrasound) 3
Immediately discontinue sacubitril-valsartan - this is the only effective treatment for drug-induced cholestasis 3
Monitor liver tests closely - normalization should occur within 3 months in most cases 3
Liver biopsy is not mandatory unless the course is severe, progressive, or prolonged 3
Important Caveats
- Do not rechallenge - this is potentially harmful and unethical 3
- Drug-induced cholestatic injury generally has a better prognosis than hepatocellular injury 3
- The case report used supportive care (magnesium isoglycyrrhizinate and polyene phosphatidylcholine) though evidence for these interventions is limited 2
- UDCA may be considered but is regarded as experimental due to lack of controlled trials 3
Bottom line: While sacubitril-valsartan-induced cholestasis is exceedingly rare, maintain clinical vigilance for hepatotoxicity, particularly during the initial months of therapy. The risk-benefit ratio remains highly favorable given the drug's proven mortality and morbidity benefits in heart failure 4, 5.